# Study of the Safety and Efficacy of a Caffeine-based Antifibrosis Cream in Patients With Breast Cancer Undergoing Radiation Therapy

> **NCT03768492** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **NYU Langone Health** · enrollment: 60 (actual)

## Conditions studied

- Carcinoma Breast

## Interventions

- **DRUG:** Caffeine anhydrous 5% added to Lipoderm Cream Base.
- **OTHER:** Lipoderm Cream Base

## Key facts

- **NCT ID:** NCT03768492
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-06-29
- **Primary completion:** 2025-12
- **Final completion:** 2027-12
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2025-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03768492

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03768492, "Study of the Safety and Efficacy of a Caffeine-based Antifibrosis Cream in Patients With Breast Cancer Undergoing Radiation Therapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03768492. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*